Evidence map›Paper›PMID 28217674›Full record

ArticleObstetrics & gynecology science2017

Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.

Min Jin Lee, Bo Seong Yun, Seok Ju Seong, Mi-La Kim, Yong Wook Jung, Mi Kyoung Kim, Hyo Sook Bae, Da Hee Kim, Ji Young Hwang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obstetrics & gynecology science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Medical Management of Symptomatic Fibroids: Worth It?Journal of obstetrics and gynaecology of India · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Min Jin LeeDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Bo Seong YunDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.ORCID 0000-0003-4352-1693
Seok Ju SeongDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Mi-La KimDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Yong Wook JungDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Mi Kyoung KimDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Hyo Sook BaeDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Da Hee KimDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
Ji Young HwangDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this study was to evaluate the effect of short-term use of selective progesterone receptor modulator (SPRM) or gonadotropin-releasing hormone (GnRH) agonist on uterine fibroid shrinkage among Korean women.

methodsThis retrospective study involved 101 women with symptomatic uterine fibroids who received ulipristal acetate (SPRM, n=51) and leuprolide acetate (GnRH agonist, n=50) for 3 months between November 2013 and February 2015. The fibroid volume was measured both before and after treatment using ultrasonography, computed tomography, and magnetic resonance imaging. The outcomes were compared between the SPRM and GnRH agonist groups.

resultsThe median rate of fibroid volume reduction after SPRM treatment was 12.4% (IQR -14.5% to 40.5%) which was significantly lower than the reduction rate observed after GnRH agonist treatment (median 34.9%, IQR 14.7% to 48.6%,

conclusionShort-term SPRM treatment yields lower volume reduction than GnRH agonist treatment in Korean women with symptomatic fibroids. Further large-scale randomized trials are needed to confirm our findings.

Indexed as

Gonadotropin-releasing hormone agonistLeiomyomaSelective progesterone receptor modulatorVolume reduction

Identifiers

PMID28217674
PMCPMC5313366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.